Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's diseaseSep 8Clinical readoutMonte Rosa Therapeutics, IncNovartis
Novartis roundup: ITP real-world data completed; three trials registered; Utah study terminatedSep 4Weekly roundup, 6 itemsDDY391inclisiran
Monte Rosa reports Q2 2026 results as MGD pipeline advances on three frontsAug 6Quarterly updateMonte Rosa Therapeutics, Inc
Novartis: Myfortic label update approved; M.D. Anderson posts endometrial trial resultsJul 31Weekly roundup, 6 itemsabelacimabDDY391